In combination with topotecan, it has a cytotoxic effect and activates the STING (STimulator of INterferon Genes) pathway, implying that ATR-TOP1 inhibition may improve response to immune checkpoint therapy in STING-low SCLC tumors [80]. The gene discussed is STING1; the disease is small cell lung carcinoma.